Kiel University

Nowcasting consumer price inflation using high-frequency scanner data: evidence from Germany

Retrieved on: 
Tuesday, April 23, 2024
Consensus, Online, Cream, Honey, Tax, Glass, MAPI, Consensus Economics, Journal of Economic Perspectives, Milk, Shower, Low-alcohol beer, Autoregressive–moving-average model, Infant, C3, Islam, Wine, Core inflation, Research Papers in Economics, National accounts, Kálmán, Barcode, Journal of International Economics, Communication, Royal Statistical Society, COVID19, Kohl (cosmetics), Natural disaster, Business, Observation, Paper, VAT, European Economic Review, Diebold Nixdorf, Blancmange, Calendar, Sunflower oil, Annual Review of Economics, Hand, C4, DESTATIS, NBER, Tinning, Razor, Forecasting, Gasoline, Coffee, European Economic Association, Cat, Journal of Monetary Economics, Journal of Applied Econometrics, Medeiros, Architecture, Oxford University Press, Producer, GfK, Quarterly Journal of Economics, Margarine, NCBS, Starch, Political economy, Consistency, COVID-19, Consensus decision-making, Website, MIDAS, Behavior, Deutsche Bundesbank, PPI, World Bank, Collection, Medical classification, Orange, Eurozone, Butter, FMCG, Noise, Travel, Clothing, History, Inflation, Liver, International economics, Journal of Political Economy, BSI, OLS, Statistics, Consumer, PDF, University of Chicago, Classification, ECB, Fats, Policy, Multi, WOB, Outline, C6, Mincing, Canadian International Council, Social science, Perfume, University of California, Berkeley, Journal of Forecasting, Federal Reserve Bank, JEL, L1, Journal, Research, Candle, Food, TPD, Credit, Spice, LPG, Janssen, Marmalade, Superior, Literature, Chocolate, Beef, Kiel University, European Central Bank, Natural gas, HICP, Monetary economics, Yogurt, Section 5, ILO, Bermingham, Price, GTIN, Cheese, Macroeconomics, Growth, Beck, XJ, Government, De Beer, Supermarket, Ice cream, Naturally, C53, Corn flakes, BIS, Biscuit, LASSO, Petroleum, A.2, Poultry, Accuracy and precision, Application, White, Lettuce, Risk, ESCB, University of Siegen, OECD, Chapter One, Lipstick, Sack, XT, BIC, Garlic, Consumption, Sokol, Meat, VAR, Database, Section 3, Rusk, American Economic Journal, Royal, Curd, Overalls, Lamb, Great Lockdown, Fruit, Economy, COICOP, International Journal of Forecasting, Aftershave, Section 2, Nonparametric statistics, Attention, Conference, CPI, Heat, Public economics, Common sunflower, Nowcasting, American Economic Review, Computational Statistics (journal), GFK, COVID-19 pandemic, Exercise, Shock, Running, UNECE, Edible, Gambling, Banco, Rigid transformation, European Commission, Frozen, C.2, PRISMA, Official statistics, Concept, Drink, Transaction data, Somatosensory system, Punctuality, Altbier, Food prices, Response, GDP, Index, E31, Cabinet of Germany, Holiday, Machine learning, Series, Green, Whisky, Vegetable, Cola, Journal of Econometrics, Sadik Harchaoui, University, Aggregate, World Bank Group, B.1, Use, Book, Economic statistics, Civil service commission, 1L, Apple, Bread, Filter, Central bank, Brandeis University, Economic Modelling, Bank, Barkan, Roulade, Dairy product, Neural network, Reproduction, IMF, Section, ID, Data, D4L, Cryptocurrency

Key Points: 

    EQS-News: Fielmann Group bids farewell to its founder Guenther Fielmann

    Retrieved on: 
    Friday, January 5, 2024

    It is with profound sorrow that we announce the passing of Fielmann Group’s founder and long-standing Chairman of the Board, Professor Guenther Fielmann.

    Key Points: 
    • It is with profound sorrow that we announce the passing of Fielmann Group’s founder and long-standing Chairman of the Board, Professor Guenther Fielmann.
    • Guenther Fielmann had a clear vision and a long-term plan for his succession: In 2012, he secured the Fielmann family's decisive influence for future generations by transferring the majority stake in the Fielmann Group to a family foundation.
    • Before Fielmann, people with statutory health insurance were "socially stigmatised" by their glasses, as Guenther Fielmann put it.
    • The Fielmann family, represented by Guenther Fielmann’s children, Sophie and Marc, founded the charitable Fielmann Foundation this week.

    Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

    Retrieved on: 
    Wednesday, October 18, 2023

    Avextra announces its support of BELCANTO; a Phase 2 double-blind clinical trial initiated by Prof. Dr. med.

    Key Points: 
    • Avextra announces its support of BELCANTO; a Phase 2 double-blind clinical trial initiated by Prof. Dr. med.
    • As the first project within this alliance, Avextra is delighted to announce its support of its first Phase 2 study – a randomised, double-blind, placebo-controlled clinical trial, under the name BELCANTO.
    • The trial will be mainly conducted at Kiel University along with three other leading medical centres across Germany, enrolling approximately 170 oncology patients.
    • "BELCANTO is an ideal project to launch Avextra’s Alliance for Evidence-based Cannabis Medicine," said Dr. Bernhard Babel, CEO, at Avextra.

    OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio

    Retrieved on: 
    Tuesday, April 18, 2023

    In addition, preclinical characterization data on CLEC-1 (new myeloid immune checkpoint) binding mechanism will also be presented on April 19.

    Key Points: 
    • In addition, preclinical characterization data on CLEC-1 (new myeloid immune checkpoint) binding mechanism will also be presented on April 19.
    • Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “We are very pleased to share our latest scientific advances with the leading international cancer scientific community.
    • The escalation Phase 1 clinical trial data on selective SIRPα antagonist BI 765063 showed preliminary clinical efficacy results in monotherapy and in combination with PD1 inhibitor ezabenlimab in patients with advanced solid tumors.
    • Two clinical studies are ongoing in inflammatory diseases: a phase 2a study conducted in primary Sjögren’s syndrome by Servier and a Phase 2 study conducted in ulcerative colitis by OSE Immunotherapeutics.